(Q40694495)

English

Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.

scientific article published on November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Katsuyuki Kuratsukuri

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Tomomichi Sone

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Ching Y Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Nobuyasu Nishisaka

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Richard F Jones

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Gabriel P Haas

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

1 November 2002

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

244-249

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Antibody-targeted immunotherapy for treatment of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

pEF-BOS, a powerful mammalian expression vector

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

New treatment strategies in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

PSMA specific antibodies and their diagnostic and therapeutic use.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Prostate-specific membrane antigen.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10700

21 January 2018

Identifiers

10.1002/IJC.10700

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40694495&oldid=1773973230"